• Alzheimer's disease;
  • metals;
  • mucosal vaccination;
  • prion;
  • vaccine


  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References

Alzheimer's and prion diseases belong to a category of conformational neurodegenerative disorders [Prusiner SB (2001) N Eng J Med344, 1516–1526; Sadowski M & Wisniewski T (2007) Curr Pharm Des 13, 1943–1954; Beekes M (2007) FEBS J 274, 575]. Treatments capable of arresting or at least effectively modifying the course of disease do not yet exist for either one of these diseases. Alzheimer's disease is the major cause of dementia in the elderly and has become an ever greater problem with the aging of Western societies. Unlike Alzheimer's disease, prion diseases are relatively rare. Each year only approximately 300 people in the USA and approximately 100 people in the UK succumb to various forms of prion diseases [Beekes M (2007) FEBS J 274, 575; Sigurdsson EM & Wisniewski T (2005) Exp Rev Vaccines 4, 607–610]. Nevertheless, these disorders have received great scientific and public interest due to the fact that they can be transmissible among humans and in certain conditions from animals to humans. The emergence of variant Creutzfeld–Jakob disease demonstrated the transmissibility of the bovine spongiform encephalopathy to humans [Beekes M (2007) FEBS J 274, 575]. Therefore, the spread of bovine spongiform encephalopathy across Europe and the recently identified cases in North America have put a large human population at risk of prion infection. It is estimated that at least several thousand Britons are asymptomatic carriers of prion infections and may develop variant Creutzfeld–Jakob disease in the future [Hilton DA (2006) J Pathol 208, 134–141]. This delayed emergence of human cases following the near elimination of bovine spongiform encephalopathy in the UK may occur because prion disease have a very prolonged incubation period, ranging from months to decades, which depends on the amount of inoculum, the route of infection and the genetic predisposition of the infected subject [Hilton DA (2006) J Pathol 208, 134–141]. Therefore, there is a great need for effective therapies for both Alzheimer's disease and prion diseases.




Alzheimer's disease



apolipoprotein E


blood–brain barrier


bovine spongiform encephalopathy


congophilic amyloid angiopathy


central nervous system


chronic wasting disease


dendritic cell


Gerstmann–Sträusler–Scheinker syndrome


prion protein


soluble Aβ


sporadic CJD




variant Creutzfeld–Jakob disease


  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References

Alzheimer's disease (AD) and prion disease belong to a category of conformational disorders showing substantial overlap in pathologic mechanism [1–3]. The basic pathomechanism in both disorders is related to a conformational change of normally expressed proteins: amyloid-β (Aβ) in AD and the prion protein (PrP) in prion disease (Fig. 1) [4,5]. This occurs without an alteration in the amino-acid sequence of the proteins. Aβ is a 40–43 amino acid peptide, which, in AD, self-assembles into toxic oligomers and fibrils that accumulate in the brain, forming plaques and deposits in the walls of meningocephalic vessels [6,7]. The same peptide can be detected in most physiological fluids, such as serum or cerebrospinal fluid, where it is called soluble Aβ (sAβ) [7]. PrPC (C-cellular) is a 209 amino acid, cell membrane anchored protein expressed at highest levels by neurons and follicular dendritic cells of the immune system. In the setting of prion disease, this protein undergoes a transformation to toxic PrPSc (Sc-scrapie) [8–10]. Fibrillar Aβ and PrPSc have a high β-sheet content which renders them insoluble, resistant to proteolytic degradation and toxic to neurons. Neurological symptoms in AD and prion disease are directly related to loss of neurons and synaptic connections. Oligomeric and fibrillar Aβ can be directly neurotoxic and/or can promote formation of neurofibrillary tangles [7]. Both fibrillar Aβ and PrPSc are capable of forming amyloid deposits. The presence of amyloid deposits is necessary for making the diagnosis of AD [11,12]. Abundant amyloid deposits composed of PrPSc (full length or fragments) are a neuropathological hallmark of variant Creutzfeld–Jakob disease (vCJD), Gerstmann–Sträusler–Scheinker syndrome (GSS), and kuru [13]. They are also present in 10% of sporadic CJD (sCJD) cases [9].


Figure 1.  Conversion of sAβ peptide or PrPC to their pathological β-sheet conformers is a key step in the pathogenesis of AD and prionoses, respectively. In AD, these β-sheet rich structures consist of oligomers, protofibrils and fibrils that form plaques within the brain parenchyma or deposit in the cerebrovasculature. A comparable entity in prion diseases consists of the proteinase K resistant scrapie form of the prion protein (PrPSc) that, in certain prion diseases, fibrillizes and deposits as plaques within the brain. This process is facilitated by various pathological chaperones as well as several metals. The aim of most therapeutic interventions for these conformational disorders is to reduce the amount of the substrate (sAβ, PrPC) and/or its availability for this structural alteration; interfere with the conversion either directly or indirectly (via the pathological chaperones or metals); and promote removal of the disease-associated conformers.

Download figure to PowerPoint

A number of proteins may actively promote the conformational transformation of these disease specific proteins and stabilize their abnormal structure. Examples of such proteins in AD include apolipoprotein E (apoE), especially its E4 isoform [13,14], α1-antichymotrypsin (ACT) [15] or C1q complement factor [16,17] (Fig. 1). In their presence, the formation of Aβ fibrils in a solution of sAβ is much more efficient [13,15]. These ‘pathological chaperone’ proteins have been found histologically and biochemically in association with fibrillar Aβ deposits [18] but not in preamyloid aggregates, which are not associated with neuronal loss [19]. Similarly, in prion disease, extensive data points toward the existence of an unidentified protein X actively involved in the conversion of PrPC into PrPSc[20].

AD and prion diseases exist as sporadic and inherited illnesses. In addition, prion disease can be transmitted from one subject to another. In experimental model settings, some evidence also exists for the infectivity of AD [21,22]. An important event in the pathomechanism of AD is thought to be reaching a critical concentration of sAβ and/or chaperone proteins in the brain, at which point the conformational change occurs [23]. This leads to the formation of Aβ aggregates, initiating a neurodegenerative cascade. In sporadic AD, this occurs due to an age-associated overproduction of Aβ, impaired clearance from the brain, and/or influx into the central nervous system (CNS) of sAβ circulating in the serum [24]. Inherited forms of AD are associated with various genetic defects, resulting in overproduction of total sAβ, or more fibrillogenic Aβ 1–42 species [25].

Sporadic prionoses like sCJD are thought to result from the spontaneous conversion of PrPC into PrPSc[26]. The mechanisms that stabilize PrPC structure are largely unknown but, once PrPSc assumes its pathological conformation, it can bind to PrPC and induce a conformation change. This starts a self-perpetuating vicious cycle allowing PrPSc to replicate without DNA, using the host cell's PrPC as a template [9,26]. Most inherited prionoses such as GSS or inherited forms of CJD are the result of a point mutation in PrPC that increases the propensity for it to assume an abnormal conformation. Virtually all genetic defects implicated in familial forms of AD and prionoses are inherited in an autosomal dominant fashion. Unlike AD, prionoses can be easily transmitted between subjects of the same species. Transmissibility of prionoses between different species is generally ineffective due to differences in the PrP sequence. The phenomenon protecting one species from acquiring a prion disease from another is called ‘the species barrier’. Therefore, scrapie (a prionosis affecting sheep) is not transmissible to humans. The species barrier does not provide absolute protection; therefore, transmission of scrapie to cattle and transmission of bovine spongiform encephalopathy (BSE) from cattle to humans results in the emergence of vCJD. In transmissible prionoses, exogenous PrPSc present in the inoculum is responsible for the conformational transformation of host PrPC. Upon entering an organism, PrPSc initially replicates within the lymphoreticular organs, including the spleen, lymph nodes and tonsils, for months to years prior to neuroinvasion and the onset of neurological symptoms. Therefore, infected but asymptomatic individuals are a reservoir of infectious material. This occurs because PrPC is expressed by follicular dendritic cells and other lymphoid cells [27]. Accumulation of PrPSc in the lymphatic organs of presymptomatic humans infected with BSE has been demonstrated by immunohistochemistry [28]. PrPSc replication is possible because it does not elicit an immune response [29]. This is related to the inability of the immune system to distinguish between PrPC and PrPSc.

Vaccination approaches for AD

  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References

Vaccination was the first treatment approach demonstrated to have genuine impact on disease process, at least in animal models of AD. Vaccination of AD transgenic (Tg) mice with Aβ1–42 or Aβ homologous peptides coinjected with Freund's adjuvant prevented the formation of Aβ deposition and, as a consequence, eliminated the behavioral impairments that are related to Aβ deposition [30–35]. Similar effects on Aβ load and behavior have been demonstrated in AD Tg mice by peripheral injections of anti-Aβ monoclonal serum indicating that the therapeutic effect of the vaccine is based primarily on eliciting a humoral response [36,37]. The striking biological effect of the vaccine in preclinical testing and the apparent lack of side-effects in AD Tg mice encouraged Elan/Wyeth to launch clinical trials with a vaccine designated as AN1792 which contained preaggregated Aβ1–42 and QS21 as an adjuvant. This type of vaccine design was aimed to induce a strong cell-mediated immune response because QS21 is known to be a strong inducer of Th-1 lymphocytes [38]. The initial safety testing of AN1792 in phase I of the trial did not demonstrate any adverse effects. The phase II of the trial was prematurely terminated when 6% of vaccinated patients manifested symptoms of acute meningoencephalitis [38,39]. An autopsy performed on one of the affected patients revealed an extensive cytotoxic T-cell reaction surrounding some cerebral vessels; however, analysis of the Aβ load in the brain cortex suggested that Aβ clearance had occurred [40]. It appeared that the immune reaction triggered by AN1792 was a double-edge sword, where the benefits of a humoral response against Aβ were overshadowed in some individuals by uncontrolled cytotoxicity [41]. Not all patients who received AN1792 responded with antibody production. The majority mounted a humoral response and showed a modest but statistically significant cognitive benefit demonstrated as an improvement on some cognitive testing scales compared to baseline and a slowed rate of disease progression compared to patients who did not form antibodies [42]. The follow-up data from the ‘Zurich’s cohort', who are a subset of the Elan/Wyeth trial followed by Dr Nitsch's group [42,43], indicated that the vaccination approach may be beneficial for human AD patients but that the concept of the vaccine has to be redesigned.

It appears that a humoral response elicited by the vaccine has at least two mechanisms of action and both of these are thought to be involved in amyloid clearance [44,45]. Conformational selective anti-Aβ serum may target Aβ deposits in the brain [43] leading to their disassembly [46,47] and elicit Fc mediated phagocytosis by microglia cells. The second mechanism by which anti-Aβ serum likely prevents Aβ deposition is the creation of a ‘peripheral sink’ effect, where the removal of excess sAβ circulating in the blood stream leads to sAβ being drawn out from the brain [31,34, 47,48]. This peripheral sink mechanism is likely to be the dominant means of reducing Aβ peptides in the brain.

The cause(s) for the toxicity in 6% of the Elan trial patients are not entirely known; however, from the available clinical and limited autopsy data, it is thought that an excessive Th-1 cell-mediated response within the brain was to blame [49]. The concept of a redesigned AD vaccine puts emphasis on avoiding this cell-mediated response in the following ways: (a) avoiding stimulation of Th-1 lymphocytes so the vaccine could potentially elicit a purely humoral response; (b) using nontoxic and nonfibrillogenic Aβ homologous peptides, so that the immunogen can not produce any direct toxicity; and (c) enhancing the peripheral sink effect rather than central action.

Passive transfer of exogenous anti-Aβ monoclonal serum appears to be the easiest way to fulfill the goal of providing anti-Aβ serum without risk of uncontrolled Th-1 mediated autoimmunity. AD Tg model mice treated this way had a significantly reduced Aβ level and demonstrated cognitive benefit [36,37]. The major drawbacks of this approach are the high cost, limited half-life of monoclonal antibodies (2–21 days depending on class and isoform) and the potential for inducing serum sickness with resultant complications such as renal failure or lymphomas. Nevertheless, clinical trials for passive immunization trials are underway. Alternative approaches for passive immunization which are less likely to be associated with toxicity, are use of Fv fragments or mimetics of the active antibody binding site.

Another potential source of toxicity in association with passive immunization is cerebral hemorrhage. The mechanism of this hemorrhage is thought to be inflammation in association with cerebral amyloid deposits (congophilic amyloid angiopathy; CAA) that weakens the blood vessel wall. Several reports have shown an increase in microhemorrhages in different AD mouse models following passive intraperitoneal immunization with different monoclonal antibodies with high affinity for Aβ plaques and CAA [50–52]. The risk of microhemorrhage following active immunization in animal models has not been fully assessed. It has not been a problem in our own active immunization studies [34,35], but has been reported in one study [53]. Furthermore, the clinical trial data from the limited number of autopsied cases suggests that vascular amyloid was not being cleared and that hemorrhage may have been increased [54–56]. In one of these autopsies, numerous cortical bleeds, which are typically rare in AD patients, were evident [55]. In addition, the association of T lymphocytosis and cuffing with the cerebral vessel Aβ in these autopsies suggests a potential role of CAA and an excessive Th-1 response in the genesis of the inflammatory side-effects [57]. This is an important issue because CAA is present in virtually all AD cases, with approximately 20% of AD patients having ‘severe’ CAA [58]. Furthermore CAA is present in approximately 33% of cognitively normal elderly, control populations [59–61].

Understanding the antigenic profile of Aβ peptide, allows engineering of modifications that favor a humoral response and reduce the potential for a Th-1 mediated response. This approach has been termed altered peptide ligands. Computer models have predicted that Aβ1–42 has one major antibody binding site located on its N-terminus and two major T-cell epitopes located at the central and C-terminal hydrophobic regions encompassing residues 17–21 and 29–42, respectively [62–64]. Therefore, their elimination or modification provides a double gain by eliminating toxicity, as well as the potential for T-cell stimulation. Sigurdsson et al. [34] immunized AD Tg mice with K6Aβ1–30[E18E19], a nontoxic Aβ-homologous peptide, where the first above mentioned T-cell epitope was modified and the second removed. Polyamino acid chains coupled to its N-terminus aimed to increase the immunogenicity and solubility of the peptide. AD Tg mice vaccinated with this peptide produced mainly an IgM class antibodies and low or absent IgG titer. These animals showed behavioral improvement and a partial reduction of Aβ deposits [34,35]. One of the advantages of this design is that IgM, with a molecular mass of 900 kDa, does not penetrate the blood–brain barrier (BBB) and therefore is unlikely to be associated with any immune reaction in the brain. Like passive immunization, this type of vaccine focuses its mechanism of action on the peripheral sink. Furthermore, the IgM response is reversible because it is T-cell independent; hence memory T-cells that could maintain the immune response are not generated. Therefore, this vaccine method may potentially be safer than typical active immunization.

Mucosal vaccination can be an alternative way to achieve a primarily humoral response. This mechanism is based on the presence of lymphocytes in the mucosa of the nasal cavity and of the gastrointestinal tract. This type of response produces primarily S-IgA antibodies but, when the antigen is coadministrated with adjuvants such as cholera toxin subunit B or heat-labile Escherichia coli enterotoxin, significant IgG titer in the serum may be achieved [65,66]. A marked reduction of Aβ burden in AD Tg mice immunized this way using Aβ as an antigen has been already demonstrated [66,67]. Interestingly, this type of mucosal immunization has recently been shown to be highly effective for prion infection [68,69,70]. This promising approach requires further exploration, especially using nonfibrillar and nontoxic Aβ homologous peptides as an antigen. Mucosal immunization offers a great potential advantage in that a more limited humoral immune response can be obtained, with little or no cell-mediated immunity.

Inhibition of Aβ fibrillization

  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References

Formation of Aβ fibrils and deposition of Aβ in the brain parenchyma or in the brain's vessels occurs in the setting of increased local Aβ peptide concentrations [71]. Initially, conditions do not favor aggregation of fibrils; however, once a critical nucleus has been formed, aggregation with fast kinetics is favored. Any available monomer can then become entrapped in an aggregate or fibril. Several compounds, such as Congo red [71], anthracycline [73], rifampicin [74], anionic sulphonates [75], or melatonin [76], can interact with Aβ and prevent its aggregation into fibrils in vitro, thereby reducing toxicity. It has been further identified that certain nonfibrillogenic, Aβ homologous peptides can bind to Aβ and break the formation of β-sheet structure [77–80]. Therefore, these peptides were termed β-sheet breakers. Several modifications were used to extend serum half-life and increase BBB permeability of these peptides. Permanne et al. [81], using a BBB permeable five amino-acid long peptide (iAβ5), were able to demonstrate a reduction of Aβ load in AD Tg mice that received this peptide compared with age-matched control group which received placebo. Of interest, a similar concept of β-sheet breakers has been shown to be applicable to prion disease [82].

Extensive evidence suggests that the most toxic forms of Aβ are oligomeric aggregates [83]. There is also evidence implicating oligomeric aggregates in the mediation of PrPSc toxicity and infectivity [84,85]. Recently, compounds and antibodies have been developed that specifically target Aβ oligomers [86–88]. Similar approaches are being developed for prion oligomers.

Aβ homologous peptides can aggregate and form fibrils spontaneously in vitro; however, in vivo this process appears more dependant on the presence of Aβ pathological chaperones. This group of proteins promotes conformational transformation at certain concentrations by increasing the β-sheet content of these disease specific proteins and stabilizes their abnormal structure [89,90]. Examples of such proteins in AD include apoE, especially its E4 isoform [18,91], ACT [20] or C1q complement factor [21,22]. In their presence, the formation of Aβ fibrils in a solution of sAβ monomers becomes much more efficient [18,20]. These ‘pathological chaperone’ proteins have been found histologically and biochemically in association with fibrillar Aβ deposits [23,89,92,93] but not in preamyloid aggregates that are not associated with neuronal toxicity [24,94]. Inheritance of the apoE4 isoform has been identified as the major identified genetic risk factor for sporadic, late-onset AD [95] and correlates with an earlier age of onset and greater Aβ deposition, in an allele-dose-dependent manner [19,95,96]. In vitro, all apoE isoforms can propagate the β-sheet content of Aβ peptides promoting fibril formation [92], with apoE4 being the most efficient [18]. The critical dependence of Aβ deposition in plaques on the presence of apoE has also been confirmed in AD Tg APPV717F/apoE–/– mice which have a delayed onset of Aβ deposition, a reduced Aβ load, and no fibrillar Aβ deposits. Compared to APPV717F/apoE+/+ Tg mice, APPV717F/apoE+/– mice demonstrate an intermediate level of pathology [97–100]. Neutralization of the chaperoning effect of apoE would therefore potentially have a mitigating effect on Aβ accumulation. ApoE hydrophobically binds to the 12–28 amino acid sequence of Aβ, forming SDS insoluble complexes [101–103]. Ma et al. [104] have demonstrated that a synthetic peptide homologous to 12–28 amino-acid sequence of Aβ can be used as a competitive inhibitor of the binding of full length Aβ to apoE, resulting in reduced fibril formation in vitro and increased survival of cultured neurons. The introduction of several modifications to Aβ12–28 by replacing a valine for proline in position 18, making this peptide nontoxic and nonfibrillogenic, as well as end-protection by amidation and and acetylation of the C- and N-termini, respectively, to increase serum half-life, have allowed us to use this peptide therapeutically in the APPK670N/M671L/PS1M146L double Tg mice model. Tg mice treated with Aβ12–28P for 1 month demonstrated a 63.3% reduction in Aβ load in the cortex (P = 0.0043) and a 59.5% (P = 0.0087) reduction in the hippocampus comparing to age-matched control Tg mice that received placebo [105,106]. The treated Tg mice also had a cognitive benefit [105,106]. No antibodies against Aβ were detected in sera of treated mice; therefore, the observed therapeutic effect of Aβ12–28P cannot be attributed to an antibody clearance response. This experiment demonstrates that compounds blocking the interaction between Aβ and its pathological chaperones may be beneficial for treatment of Aβ accumulation in AD [14,105,106]. Whether similar approaches can be used for prion disease remains to be determined.

Prion disease

  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References

Interest in prion disease has greatly increased subsequent to the emergence of BSE in England and the resulting appearance of vCJD in human populations. BSE arose from the feeding of cattle with prion contaminated meat and bone meal products, whereas vCJD developed following entry of BSE into the human food chain [107,108]. Since the original report in 1995, a total of 201 probable or confirmed cases of vCJD have been diagnosed, 165 in Great Britain, 21 in France, four in Ireland, three in the USA, two in the Netherlands and one each in Italy, Canada, Japan, Saudi Arabia, Portugal and Spain. Most of the patients from these countries resided in the UK during a key exposure period of the UK population to the BSE agent. It has proven difficult to predict the expected future numbers of vCJD. Mathematical analysis has given a range from 1000 to approximately 136 000 individuals who will eventually develop the disease. This broad range reflects a lack of knowledge regarding the time of incubation and the number of patients who could be infected from a given dosage of BSE agent. Because the vCJD agent is present at high levels in the lymphatic tissue, screening for PrPSc was performed on sections from lymph nodes, tonsils, and appendices archives in the UK. Three out of 12 674 randomly selected cases showed evidence of subclinical infection, leading to a prediction that approximately 4000 vCJD further cases may occur in the UK [109]. However, there is much uncertainty about such a prediction because it is not known whether all subclinical infections will progress and also whether such screening of lymphoid tissue would capture all subclinical cases. The initially predicted epidemic of vCJD does not seem to be materializing because the number of cases in the UK has declined from a peak of 28 in 2000 to five cases in 2006 [107]. A complicating factor for estimating future numbers of vCJD is the documentation of several transfusion associated cases. These occurred after incubation periods of 6–8 years. One of these disease associated donations was made more than 3 years before the donor became symptomatic, suggesting that vCJD can be transmitted from silently infected individuals [110]. The estimated risk for new cases of vCJD in other European countries looks more optimistic. In the UK, 200 000 cases of BSE were reported (it is estimated that four times this number entered the food chain), compared to approximately 5600 BSE cases in other European countries (with the highest numbers being 1590, 1030 and 986 in Ireland, Portugal and Frances, respectively). This suggests a significantly lower exposure of these populations to BSE prions. A few cases of BSE have also been reported in other parts of the world, such as Japan, the USA and Canada.

Of greater concern in North America is chronic wasting disease (CWD). This disease is now endemic in Colorado, Wyoming and Nebraska and continues to spread to other parts in the USA, initially in the Midwest but now detected as far East as New York State [111,112]. Most vulnerable to CWD infection are white tailed deer and the disease is now found in areas with a large population of these animals, which indicates that its prevalence can be expected to increase substantially in the future. The occurrence of CJD among three young deer hunters from this same region raised the speculation of transmission of the CWD to humans [113]. However, autopsy of these three subjects did not reveal the extensive amyloidosis characteristic of vCJD and CWD [114]. However like BSE, CWD is transmissible to nonhuman primates and transgenic mice expressing human PrPC[115,116]. Therefore, the possibility of such transmission needs to be closely monitored. CWD is similar to BSE in that the peripheral titers of the prion agent are high. PrPSc has been detected in both muscle and saliva of CWD infected deer [117,118].

Vaccination as a therapeutic approach for prionoses

  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References

The prion protein is a self-antigen; hence, prion infection is not known to elicit a classical immune response. In fact, the immune system is involved in the peripheral replication of the prion agent and its ultimate access to the CNS [29,68]. This involvement is further supported by the observation that immune suppression with, for example, splenectomy or immunosuppressive drugs, increases the incubation period. This interval, during which time the prion agent replicates peripherally, without producing any symptoms, is quite long, lasting many months in experimental animals and up to 56 years in documented human cases associated with cannibalistic exposure to the prion agent [119]. Lymphatic organs such as the spleen, tonsils, lymph nodes or gut associated lymphoid tissue contain high concentrations of PrPSc long before PrPSc replication starts in the brain [27,120,121]. Cells found to be particularly important for peripheral PrPSc replication are the follicular dendritic cells (DC) and the migratory bone-marrow derived DC [121,122]. DC from infected animals are capable of spreading the disease [122]. An emerging therapeutic approach for prion infection is immunomodulation [68,70,123].

Currently, there is no treatment that would arrest and/or reverse progression of prion disease in nonexperimental settings, although many approaches have been tried [124]. Partly due to the success in AD models discussed above, similar experiments with anti-PrP serum were initiated in prion infectivity culture models as well as active and passive immunization studies in rodent models. Earlier in vivo studies showed that infection with a slow strain of PrPSc blocked expression of a more virulent fast strain of PrP, mimicking vaccination with a live attenuated organism [125]. In tissue culture studies, anti-PrP serum and antigen binding fragments directed against PrP were shown to inhibit prion replication [126–128]. Although we first demonstrated that active immunization with recombinant PrP delayed the onset of prion disease in wild-type mice, the therapeutic effect was relatively modest and, eventually, all the mice succumbed to the disease [129]. This limited therapeutic effect may be explained by the observation that antibodies generated against prokaryotic PrP often do not have a high affinity towards PrPC[130], although, in our studies, the increase in the incubation period correlated well with the antibody titers against PrPC. Our follow-up passive anti-PrP immunization study confirmed the importance of the humoral response, showing that anti-PrP serum is able to prolong the incubation period [131]. Subsequently, other investigators, using a much higher antibody dosage, were able to completely prevent disease onset in mice exposed to PrPSc provided that passive immunization was initiated within 1 month of exposure [132]. This type of approach could be used immediately following accidental exposure in humans to prevent future infection. However, passive immunization has not been found to be effective closer to the clinically symptomatic stages of prion infection. Also, passive immunization would be an approach that is too costly for animal prion diseases.

In the development of immunotherapeutic approaches targeting a self-antigen, designing a vaccine avoiding auto-immune related toxicity is a major concern. The emerging data from AD targeting immunization is that toxicity is due to excessive cell-mediated immunity within the CNS, whereas the therapeutic response is linked to humoral immunity. In addition, toxicity could be partially related to the immunogen and/or to the adjuvant used; in the human AD vaccination trial, fibrillar Aβ1–42 was used as an immunogen. This peptide is well characterized to be toxic. Hence, we have been promoting the use of nonamyloidogenic derivatives as immunogens for protein conformational disorders, including AD and prion disease [31,34,38]. How significant an issue direct toxicity of the immunogen may be for prion vaccination remains unclear. Unlike the Aβ peptide used for vaccination in AD models, direct application of recombinant PrP has not been shown to be toxic. However, this issue has not been investigated as thoroughly as in the Alzheimer's field and remains controversial. Several lines of evidence suggest that intracellular accumulations of PrPSc promote neurodegeneration [133].

A potential ideal means of using immunomodulation to prevent prion infection is by mucosal immunization. One important reason for this is that the gut is the major route of entry for many prion diseases such as CWD, BSE and vCJD. Furthermore, mucosal immunization can be designed to induce primarily a humoral immune response, avoiding the cell-mediated toxicity that was seen in the human AD vaccine trial. In addition, mucosal vaccination has the advantage that it is unlikely to induce significant immune response within the brain. Although it has been shown that reduced levels or absence of CNS PrPC by, for example, conditional ablation by genetic manipulation of neuronal PrPC[134] can prevent clinical prion infection, it is likely that the immunological targeting of neuronal PrP would be associated with inflammatory toxicity. Recently, we have been developing prion vaccines that target gut associated tissue, the main site of entry of the prion agent. One of our approaches is to express PrP in attenuated Salmonella strains as a live vector for oral vaccination, which has resulted in prevention or significant delay of prion disease in mice [69]. Live attenuated strains of Salmonella enterica have been used for many years as vaccines against salmonellosis and as a delivery system for the construction of multivalent vaccines with a broad application in human and veterinary medicine [135]. A main advantage for this system is that the safety of human administration of live attenuated Salmonella has been extensively confirmed in humans and animals [136,137]. Ruminants and other veterinary species can be effectively immunized by the oral route using attenuated Salmonella, to induce humoral mucosal responses [138,139]. We are currently exploring ways to increase the efficacy even further. In these studies, the mucosal IgA anti-PrP titer correlates well with the delay or prevention of prion infection, further supporting the importance of the humoral response for the therapeutic effect. Salmonella target M-cells, antigen sampling cells in the intestines, which may also be important for uptake of PrPSc[27,68,121]. Hence, this approach is more targeted than prior vaccination studies, likely explaining the improved efficacy. By exploring other strains of attenuated Salmonella, using different bacteria or oral adjuvants, and/or by altering the expression levels or sequence of the PrP antigen, it is likely that the percentage of uninfected animals can be improved. Our recent work utilizing this approach indicates that complete protection to clinical prion infection via an oral route is possible. Overall, this approach holds great promise as an inexpensive prophylactic immunotherapy to prevent the spread of prion disease, particularly in animals at risk and perhaps eventually in certain high risk human populations.

Metal chelation for prion and AD

  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References

Metal chelation is emerging as an important therapeutic approach for AD, which is currently in clinical trial [140,141]. This approach for AD is reviewed elsewhere in this minireview series. Importantly, modulation of metal levels, in particular copper, has been shown to be important for the conversion of PrPC to PrPSc, highlighting another similarity between AD and prion diseases [10]. Copper binding is thought to be part of the normal function of PrPC[142–144]. The binding of copper to PrPC gives the complex antioxidant activity [145,146]; hence, it has been suggested that the reduced copper binding of PrPSc with a consequent reduction of antioxidant activity is part of the pathogenesis of prion disease [147]. This hypothesis has been supported by the finding that copper is reduced up to 50% in the brains of sporadic CJD patients [148]. How copper binding influences the PrPC to PrPSc conversion is complex [10,149]. We were the first to show that, similar to studies in AD Tg models, metal chelation can be used therapeutically [150] in prion infection. Our studies indicated that penicillamine, a copper chelator, prolongs the incubation period of scrapie in mice [150]. Consistent with this observation, the presence of copper has also been shown to stabilize the PrPSc conformation using preformed fibrils [151–158], as well as to induce aggregation of the prion peptide 106–126 [159]. Some tissue culture studies of prion infection have also suggested that copper chelators are suitable candidates for antiprion drugs [160]. However, there are conflicting reports indicating that the interaction between copper and PrP is likely to be quite complex. For example, copper has been shown to inhibit the in vitro conversion of recombinant PrP into amyloid fibrils but, also in contrast, to enhance the proteinase K resistance of preformed fibrils [157]. These findings indicate that copper may have a dual and opposite effect on prion propagation. It may both inhibit prion replication and prevent clearance of potentially infectious forms of the prion protein. Furthermore, copper treatment has also been shown to inhibit PrPSc amplification in reactions where brain derived PrPC was used as a seed [161], as well as delaying the onset of clinical disease in scrapie infected hamsters [162]. In addition, it has been shown that physiological levels of copper promote internalization of PrPC[163]. The interaction between PrPC and copper was found to be the overriding factor in stimulating the internalization response with other metals showing no effect. The decrease in detectable levels of PrPC at the cell surface following copper treatment was found to be the result of internalization rather than loss into the surrounding environment [163]. Such internalization would limit the exposure of PrPC to conversion from exogenous PrPSc; however, because cytoplasmic forms of PrP have been linked to neurodegeneration [133], increased internalization could also be deleterious in some settings. Copper has also been shown to have immunomodulatory effects [164] and, as discussed earlier, the immune system can have profound effects on prion infection. Hence, it appears that the deleterious or beneficial role of copper in prion infection might vary depending on which function predominates under the distinct experimental conditions being used. Nevertheless, it is clear that a greater understanding of the role of metal binding in prion infection presents a therapeutic opportunity.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References

Immunization appears to be an effective therapeutic method for prevention of Aβ deposition and cognitive decline in AD, provided that cell-mediated auto-immune toxicity can be avoided. The second generation AD vaccines, which are under development, are based on nontoxic and nonfibrillar Aβ homologous peptides that are modified to eliminate the potential for inducing cellular immunity, and elicit primarily a humoral response. Other related approaches include direct administration of antibodies that target Aβ. These interventions would likely favor a peripheral sink effect, clearing soluble Aβ from the blood stream and inducing efflux of Aβ from the brain. Additional potentially synergistic therapeutic approaches for AD would include blocking the interaction of Aβ with its ‘pathological chaperones’ such as apoE, as well as use of β-sheet breaker compounds. Immunization approaches could be used for sporadic AD, familial AD, and AD associated with Down's syndrome. The effectiveness of treatment would depend on its initiation early in the disease course. Therefore, such a treatment needs to coincide with the development of a procedure for the detection and monitoring of Aβ deposits.

Both active and passive immunization appear to be effective in prevention of prion infections in animal models. Further studies are needed to develop specific protocols applicable for human use. Active immunization, using especially mucosal immunization could be used to prevent spread of BSE through the oral route, whereas passive immunization protocols would be more appropriate for subjects accidentally infected with prion contaminated material (e.g. blood transfusion or organ transplant). Effective immunization for prion infections works through prevention of entry of PrPSc via the gut and/or neutralization of PrPSc replicating in the peripheral lymphoreticular system.

Metal chelation is another promising therapeutic approach for AD, which is currently undergoing clinical trials. Similar approaches are just emerging for prion diseases. However, a greater understanding of the role of copper and other metals in the PrPC to PrPSc conversion is needed before this therapeutic strategy can be effectively harnessed for prion infection.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Vaccination approaches for AD
  5. Inhibition of Aβ fibrillization
  6. Prion disease
  7. Vaccination as a therapeutic approach for prionoses
  8. Metal chelation for prion and AD
  9. Conclusions
  10. Acknowledgements
  11. References
  • 1
    Prusiner SB (2001) Neurodegenerative diseases and prions. N Eng J Med 3444, 15161526.
  • 2
    Wisniewski T, Sigurdsson EM, Aucouturier P & Frangione B (2001) Conformation as a therapeutic target in the prionoses and other neurodegenerative conditions. In Molecular and Cellular Pathology in Prion Disease (Baker HF, ed.), pp. 223236. Humana Press, Totowa, NJ.
  • 3
    DeArmond SJ (1993) Alzheimer's disease and Creutzfeldt-Jakob disease: overlap of pathogenic mechanisms. Curr Opin Neurol 6, 872881.
  • 4
    Sadowski M & Wisniewski T (2004) Vaccines for conformational disorders. Exp Rev Vaccines 3, 89100.
  • 5
    Sigurdsson EM (2006) Immunotherapy for conformational disorders. Curr Pharm Des 12, 25692585.
  • 6
    Small DH & Cappai R (2006) Alois Alzheimer and Alzheimer's disease: a centennial perspective. J Neurochem 99, 708710.
  • 7
    Walsh DM & Selkoe DJ (2007) Abeta oligomers − a decade of discovery. J Neurochem 101, 11721184.
  • 8
    DeArmond SJ & Prusiner SB (1995) Etiology and pathogenesis of prion diseases. Am J Pathol 146, 785811.
  • 9
    Sadowski M, Verma A & Wisniewski T, (2007) Prion diseases. In Neurology in Clinical Practice, 5th edn. Butterworth-Heinemann., Philadelphia, PA.
  • 10
    Caughey B & Baron GS (2006) Prions and their partners in crime. Nature 443, 803810.
  • 11
    Mirra SS, Gearing M & Nash F (1997) Neuropathologic assessment of Alzheimer's disease. Neurology 49, S14S16.
  • 12
    Wisniewski HM, Bancher C, Barcikowska M, Wen GY & Currie J (1989) Spectrum of morphological appearance of amyloid deposits in AD. Acta Neuropathol 78, 337347.
  • 13
    Wisniewski T, Castaño EM, Golabek AA, Vogel T & Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145, 10301035.
  • 14
    Sadowski M & Wisniewski T (2006) Apolipoproteins in different amyloidoses. In Protein Misfolding, Aggregation and Conformational Diseases (Uversky VN, ed.). Springer, New York, NY.
  • 15
    Ma J, Yee A, Brewer HB Jr, Das S & Potter H (1994) Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 9294.
  • 16
    Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ & Anderson DH (2002) The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 99, 1183011835.
  • 17
    Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O'Leary C, Wilcock D, Morgan D & Gordon MN (2003) Increased fibrillar beta-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res 28, 8393.
  • 18
    Wisniewski T, Lalowski M, Golabek AA, Vogel T & Frangione B (1995) Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345, 956958.
  • 19
    Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M & Wegiel J (1998) Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 57, 674683.
  • 20
    Telling GC, Haga T, Torchia M, Tremblay P, DeArmond SJ & Prusiner SB (1996) Interactions between wild-type and mutant prion proteins modulate neurodegeneration transgenic mice. Genes Dev 10, 17361750.
  • 21
    Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL et al. (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313, 17811784.
  • 22
    Walker LC, LeVine H III, Mattson MP & Jucker M (2006) Inducible proteopathies. Trends Neurosci 29, 438443.
  • 23
    Wisniewski T, Ghiso J & Frangione B (1994) Alzheimer's disease and soluble Aβ. Neurobiol Aging 15, 143152.
  • 24
    Shibata M, Yamada S, Kumar S, Calero M, Bading J, Frangione B, Holtzman D, Miller CA, Strickland DK, Ghiso J et al. (2000) Clearance of Alzheimer's amyloid-Β 1–40 peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J Clin Invest 106, 14891499.
  • 25
    Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52, 313.
  • 26
    Beekes M (2007) Prions and prion diseases. FEBS J 274, 575.
  • 27
    Beekes M & McBride PA (2007) The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies. FEBS J 274, 588605.
  • 28
    Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Penney M, Ritchie D & Ironside JW (2002) Accumulation of prion protein in tonsil and appendix: review of tissue samples. Br Med J 325, 633634.
  • 29
    Aucouturier P, Carp RI, Carnaud C & Wisniewski T (2000) Prion diseases and the immune system. Clin Immunol 96, 7985.
  • 30
    Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al. (1999) Immunization with amyloid-Β attenuates Alzheimer disease-like pathology in the PDAPP mice. Nature 400, 173177.
  • 31
    Sigurdsson EM, Scholtzova H, Mehta P & Frangione B & Wisniewski T (2001) Immunization with a non-toxic/non-fibrillar amyloid-Β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 159, 439447.
  • 32
    Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D et al. (2001) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982985.
  • 33
    Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J et al. (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979982.
  • 34
    Sigurdsson EM, Knudsen EL, Asuni A, Sage D, Goni F, Quartermain D, Frangione B & Wisniewski T (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-Β derivatives. J Neurosci 24, 62776282.
  • 35
    Asuni A, Boutajangout A, Scholtzova H, Knudsen E, Li Y, Quartermain D, Frangione B, Wisniewski T & Sigurdsson EM (2006) Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur J Neurosci 24, 25302542.
  • 36
    Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of alzheimer disease. Nat Med 6, 916919.
  • 37
    DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM & Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98, 88508855.
  • 38
    Wisniewski T & Frangione B (2005) Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. Brain Pathol 15, 7277.
  • 39
    Wisniewski T (2005) Practice point commentary on ‘Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial. Nat Clin Pract Neurol 1, 8485.
  • 40
    Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H & Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9, 448452.
  • 41
    Sadowski M & Wisniewski T (2007) Disease modifying approaches for Alzheimer’s pathology. Curr Pharm Des 13, 19431954.
  • 42
    Hock C, Konietzko U, Straffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E et al. (2003) Antibodies against Β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547554.
  • 43
    Hock C, Konietzko U, Paspassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E & Nitsch RM (2002) Generation of antibodies specific for Β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8, 12701276.
  • 44
    Golde TE (2006) Disease modifying therapy for AD? J Neurochem 99, 689707.
  • 45
    Kennedy GJ, Golde TE, Tariot PN & Cummings JL (2007) Amyloid-based interventions in Alzheimer's disease. CNS Spectr 12, 114.
  • 46
    Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D & Hyman BT (2001) Imaging of amyloid-Β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7, 369372.
  • 47
    Solomon B, Koppel R, Frankel D & Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94, 41094112.
  • 48
    Sigurdsson EM, Wisniewski T & Frangione B (2002) A safer vaccine for Alzheimer's disease? Neurobiol Aging 23, 10011008.
  • 49
    Robinson SR, Bishop GM, Lee HG & Munch G (2004) Lessons from the AN 1792 Alzheimer vaccine: lest we forget., Neurobiol Aging 25, 609615.
  • 50
    Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM & Jucker M (2002) Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298, 13791380.
  • 51
    Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN & Morgan D (2004) Passive immunization against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1, 24.
  • 52
    Racke MM, Boone LI, Hepburn DL, Parsadanian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP et al. (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyoid beta. J Neurosci 25, 629636.
  • 53
    Wilcock DM, Jantzen PT, Li Q, Morgan D & Gordon MN (2007) Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid, Neuroscience 144, 950960.
  • 54
    Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H & Weller RO (2005) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9, 448452.
  • 55
    Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ & Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14, 1120.
  • 56
    Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L & Schenk D (2005) Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129131.
  • 57
    Gandy S & Walker L (2004) Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-B vaccination in nonhuman primates. Curr Opin Immunol 16, 607615.
  • 58
    Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109, 813836.
  • 59
    Jellinger KA & Attems J (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 229–230, 3741.
  • 60
    Fernando MS & Ince PG (2004) Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 226, 1317.
  • 61
    Zhang-Nunes SX, Maat-Schieman ML, Van Duinen SG, Roos RA, Frosch MP & Greenberg SM (2006) The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 16, 3039.
  • 62
    Jameson BA & Wolf H (1988) The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 4, 181186.
  • 63
    Singh H & Raghava GP (2001) ProPred: prediction of HLA-DR binding sites. Bioinformatics 17, 12361237.
  • 64
    Singh H & Raghava GP (2003) ProPred1: prediction of promiscuous MHC class-I binding sites. Bioinformatics 19, 10091014.
  • 65
    Lemere CA, Maron R, Selkoe DJ & Weiner HL (2001) Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20, 705711.
  • 66
    Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, Kong Q, Chen D, Ba D & He W (2003) A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14, 365379.
  • 67
    Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW & Selkoe D (2000) Nasal administration of amyloid-Β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48, 567579.
  • 68
    Sigurdsson EM & Wisniewski T (2005) Promising developments in prion immunotherapy. Exp Rev Vaccines 4, 607610.
  • 69
    Goni F, Knudsen EL, Schreiber F, Scholtzova H, Pankiewicz J, Carp RI, Meeker HC, Brown DR, Chabalgoity JA, Sigurdsson EM et al. (2005) Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133, 413421.
  • 70
    Wisniewski T, Chabalgoity JA & Goni F (2007) Is vaccination against transmissible spongiform encephalopathy feasible? Rev Sci tech Off int Epiz 26(1), 243251.
  • 71
    Barrow CJ, Yasuda A, Kenny PT & Zagorski MG (1992) Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol 225, 10751093.
  • 72
    Lorenzo A & Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91, 1224312247.
  • 73
    Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG & Garini P (1995) Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 92, 29592963.
  • 74
    Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H & Endo N (1996) Inhibition of amyloid Β protein aggregation and neurotoxicity by rifampicin − its possible function as a hydroxyl radical scavenger. J Biol Chem 271, 68396844.
  • 75
    Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG & Szarek WA (1995) Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1, 143148.
  • 76
    Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B & Ghiso J (1998) Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 273, 71857188.
  • 77
    Hilbich C, Kisters-Woike B, Reed J, Masters CL & Beyreuther K (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J Mol Biol 228, 114.
  • 78
    Soto C, Kindy MS, Baumann M & Frangione B (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent Β-sheet conformation. Biochem Biophys Res Commun 226, 672680.
  • 79
    Soto C, Sigurdsson EM, Morelli L, Kumar A, Castaño EM & Frangione B (1998) Β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med 4, 822826.
  • 80
    Sigurdsson EM, Permanne B, Soto C, Wisniewski T & Frangione B (2000) In vivo reversal of amyloid Β lesions in rat brain. J Neuropath Exp Neurol 59, 1117.
  • 81
    Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, Dewachter I, Banks WA, Van Leuven F & Soto C (2002) Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a Β-sheet breaker peptide. FASEB J 16, 860862.
  • 82
    Soto C, Kascsak RJ, Saborio GP, Aucouturier P, Wisniewski T, Prelli F, Kascsak R, Mendez E, Harris DA, Ironside J et al. (2000) Reversion of prion protein conformational changes by synthetic Β-sheet breaker peptides. Lancet 355, 192197.
  • 83
    Walsh DM & Selkoe DJ (2007) Abeta oligomers − a decade of discovery. J Neurochem 101, 11721184.
  • 84
    Demuro A, Mina E, Kayed R, Milton SC, Parker I & Glabe CG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280, 1729417300.
  • 85
    Novitskaya V, Bocharova OV, Bronstein I & Baskakov IV (2006) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 281, 1382813836.
  • 86
    Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM & Selkoe DJ (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60, 668676.
  • 87
    Kayed R & Glabe CG (2006) Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol 413, 326344.
  • 88
    Necula M, Kayed R, Milton S & Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282, 1031110324.
  • 89
    Wisniewski T & Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135, 235238.
  • 90
    Quinn J (2003) Vascular dementia. J Am Med Dir Assoc 4, S155S161.
  • 91
    Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD et al. (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94, 860869.
  • 92
    Golabek AA, Soto C, Vogel T & Wisniewski T (1996) The interaction between apolipoprotein E and Alzheimer's amyloid Β-peptide is dependent on Β-peptide conformation. J Biol Chem 271, 1060210606.
  • 93
    Permanne B, Perez C, Soto C, Frangione B & Wisniewski T (1997) Detection of apolipoprotein E dimeric soluble amyloid Β complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240, 715720.
  • 94
    Kida E, Golabek AA, Wisniewski T & Wisniewski KE (1994) Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. Neurosci Lett 167, 7376.
  • 95
    Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D & Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90, 96499653.
  • 96
    Rebeck GW, Reiter JS, Strickland DK & Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11, 575580.
  • 97
    Bales KR, Verina T & Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid Β-peptide deposition. Nat Genet 17, 263264.
  • 98
    Bales KR, Verina T & Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V et al. (1999) Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96, 1523315238.
  • 99
    Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y & Paul SM (1999) Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 103, R15R21.
  • 100
    Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D et al. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97, 28922897.
  • 101
    Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS & Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 19771981.
  • 102
    Wisniewski T, Golabek AA, Matsubara E, Ghiso J & Frangione B (1993) Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun 192, 359365.
  • 103
    Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L & Nordstedt C (1995) Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron 15, 219228.
  • 104
    Ma J, Brewer BH, Potter H & Brewer HB Jr (1996) Alzheimer Aβ neurotoxicity: promotion by antichymotrypsin, apoE4; inhibition by Aβ-related peptides. Neurobiol Aging 17, 773780.
  • 105
    Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews P, Fryer JD, Holtzman DM, Sigurdsson EM et al. (2004) Blocking the apolipoprotein E/Β–amyloid interaction reduces Β-amyloid toxicity and decreases Β-amyloid load in transgenic mice. Am J Pathol 165, 937948.
  • 106
    Sadowski M, Pankiewicz J, Scholtzova H, Mehta P, Prelli F & Quartermain D & Wisniewski T (2006) Blocking the apolipoproteinE/amyloid Β interaction reduces the parenchymal and vascular amyloid-Β deposition and prevents memory deficit in AD transgenic mice. Proc Natl Acad Sci USA 103, 1878718792.
  • 107
    Manson JC, Cancellotti E, Hart P, Bishop MT & Barron RM (2006) The transmissible spongiform encephalopathies: emerging and declining epidemics. Biochem Soc Trans 34, 11551158.
  • 108
    Butler R (2006) Prion diseases in humans: an update. Br J Psychiatry 189, 295296.
  • 109
    Hilton DA (2006) Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease. J Pathol 208, 134141.
  • 110
    Brown P, Brandel JP, Preese M & Sato T (2006) Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 67, 389393.
  • 111
    Williams ES (2005) Chronic wasting disease. Vet Pathol 42, 530549.
  • 112
    Aguzzi A & Sigurdson CJ (2004) Antiprion immunotherapy: to suppress or to stimulate? Nat Rev Immunol 4, 725736.
  • 113
    Belay ED, Maddox RA, Williams ES, Miller MW, Gambetti P & Schonberger LB (2004) Chronic wasting disease and potential transmission to humans. Emerg Infect Dis 10, 977984.
  • 114
    Liberski PP, Guiroy DC, Williams ES, Walis A & Budka H (2001) Deposition patterns of disease-associated prion protein in captive mule deer brains with chronic wasting disease. Acta Neuropathol 102, 496500.
  • 115
    Marsh RF, Kincaid AE, Bessen RA & Bartz JC (2005) Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus). J Virol 79, 1379413796.
  • 116
    Tamguney G, Giles K, Bouzamondo-Bernstein E, Bosque PJ, Miller MW, Safar J, DeArmond SJ & Prusiner SB (2006) Transmission of elk and deer prions to transgenic mice. J Virol 80, 91049114.
  • 117
    Angers RC, Browning SR, Seward TS, Sigurdson CJ, Miller MW, Hoover EA & Telling GC (2006) Prions in skeletal muscles of deer with chronic wasting disease. Science 311, 1117.
  • 118
    Mathiason CK, Powers JG, Dahmes SJ, Osborn DA, Miller KV, Warren RJ, Mason GL, Hays SA, Hayes-Klug J, Seelig DM et al. (2006) Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314, 133136.
  • 119
    Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ & Alpers MP (2006) Kuru in the 21st century − an acquired human prion disease with very long incubation periods. Lancet 367, 20682074.
  • 120
    Brown KL, Ritchie DL, McBride PA & Bruce ME (2000) Detection of PrP in extraneural tissues. Microsc Res Tech 50, 4045.
  • 121
    Mabbott NA & MacPherson GG (2006) Prions and their lethal journey to the brain. Nat Rev Microbiol 4, 201211.
  • 122
    Aucouturier P, Geissmann F, Damotte D, Saborio GP, Meeker HC, Kascsak R, Kascsak R, Carp RI & Wisniewski T (2001) Infected dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J Clin Invest 108, 703708.
  • 123
    Sasson J, Sadowski M, Wisniewski T & Brown DR (2005) Therapeutics and prion disease: can immunization or drugs be effective? Mini Rev Med Chem 5, 361366.
  • 124
    Trevitt CR & Collinge J (2006) A systematic review of prion therapeutics in experimental models. Brain 129, 22412265.
  • 125
    Manuelidis L (1998) Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent. Proc Natl Acad Sci USA 95, 25202525.
  • 126
    Enari M, Flechsig E & Weissmann C (2001) Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 98, 92959299.
  • 127
    Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM et al. (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739743.
  • 128
    Pankiewicz J, Prelli F, Sy MS, Kascsak RJ, Kascsak RB, Spinner DS, Carp RI, Meeker HC, Sadowski M & Wisniewski T (2006) Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci 24, 26352647.
  • 129
    Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp RI, Meeker HC, Frangione B & Wisniewski T (2002) Vaccination delays the onset of prion disease in mice. Am J Pathol 161, 1317.
  • 130
    Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N, Wopfner F, Schatzl HM, Becher B & Aguzzi A (2004) Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci USA 101, 1467014676.
  • 131
    Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, Carp RI, Meeker HC, Frangione B & Wisniewski T (2003) Anti-PrP antibodies for prophylaxis following prion exposure in mice. Neurosci Lett 336, 185187.
  • 132
    White AR, Enever P, Tayebl M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J & Hawke S (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 8083.
  • 133
    Tatzelt J & Schatzl HM (2007) Molecular basis of cerebral neurodegeneration in prion diseases. FEBS J 274, 606611.
  • 134
    Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, Powell AD, Brandner S, Jefferys JG & Collinge J (2007) Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53, 325335.
  • 135
    Mastroeni P, Chabalgoity JA, Dunstan SJ, Maskell DJ & Dougan G (2001) Salmonella: immune responses and vaccines. Vet J 161, 132164.
  • 136
    Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP, Edelman R, Perry J, Bedford P et al. (2000) Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect Immun 68, 11961201.
  • 137
    Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z et al. (2006) Evaluation of Salmonella enterica serovar typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24, 116123.
  • 138
    Villarreal-Ramos B, Manser J, Collins RA, Dougan G, Chatfield SN & Howard CJ (1998) Immune responses in calves immunised orally or subcutaneously with a live Salmonella typhimurium aro vaccine. Vaccine 16, 4554.
  • 139
    Chabalgoity JA, Moreno M, Carol H, Dougan G & Hormaeche CE (2000) A dog-adapted Salmonella typhimurium strain as a basis for a live oral Echinococcus granulosus vaccine. Vaccine 19, 460469.
  • 140
    Doraiswamy PM & Finefrock AE (2004) Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol 3, 431434.
  • 141
    Crouch PJ, Barnham KJ, Bush AI & White AR (2006) Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Drug News Perspect 19, 469474.
  • 142
    Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W et al. (1997) The cellular prion protein binds copper in vivo. Nature 390, 684687.
  • 143
    Brown DR (2002) Copper and prion diseases. Biochem Soc Trans 30, 742745.
  • 144
    Cheng F, Lindqvist J, Haigh CL, Brown DR & Mani K (2006) Copper-dependent co-internalization of the prion protein and glypican-1. J Neurochem 98, 14451457.
  • 145
    Brown DR, Nicholas RS & Canevari L (2002) Lack of prion protein expression results in a neuronal phenotype sensitive to stress. J Neurosci Res 67, 211224.
  • 146
    Brown DR, Wong B-S, Hafiz F, Clive C, Haswell SJ & Jones IM (2001) Normal prion protein has an activity like that of superoxide dismutase. Biochem J 344, 15.
  • 147
    Brown DR (2001) Prion and prejudice: normal protein and the synapse. Trends Neurosci 24, 8590.
  • 148
    Wong BS, Chen SG, Colucci M, Xie Z, Pan T, Liu T, Li R, Gambetti P, Sy MS & Brown DR (2001) Aberrant metal binding by prion protein in human prion disease. J Neurochem 78, 14001408.
  • 149
    Varela-Nallar L, Gonzalez A & Inestrosa NC (2006) Role of copper in prion diseases: deleterious or beneficial? Curr Pharm Des 12, 25872595.
  • 150
    Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp RI, Meeker HC, Prelli F, Frangione B & Wisniewski T (2003) Copper chelation delays the onset of prion disease. J Biol Chem 278, 4619946202.
  • 151
    Wong BS, Venien-Bryan C, Williamson RA, Burton DR, Gambetti P, Sy MS, Brown DR & Jones IM (2000) Copper refolding of prion protein. Biochem Biophys Res Commun 276, 12171224.
  • 152
    Wong B-S, Li R, Sasson J, Liu T, Pan T, Kang SC, Wisniewski T, Brown DR & Sy MS (2003) Mapping the antigenicity of copper-treated cellular prion protein in the scrapie form. Cell Mol Life Sci 60, 12241234.
  • 153
    McKenzie D, Bartz J, Mirwald J, Olander D, Marsh R & Aiken J (1998) Reversibility of scrapie inactivation is enhanced by copper. J Biol Chem 273, 2554525547.
  • 154
    Wong BS, Brown DR, Pan T, Whiteman M, Liu T, Bu X, Li R, Gambetti P, Olesik J, Rubenstein R et al. (2001) Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. J Neurochem 79, 689698.
  • 155
    Wong E, Thackray AM & Bujdoso R (2004) Copper induces increased beta-sheet content in the scrapie-susceptible ovine prion protein PrPVRQ compared with the resistant allelic variant PrPARR. Biochem J 380, 273282.
  • 156
    Nishina K & Jenks S & Supattapone S (2004) Ionic strength and transition metals control PrPSc protease resistance and conversion-inducing activity. J Biol Chem 279, 4078840794.
  • 157
    Bocharova OV, Breydo L, Salnikov VV & Baskakov IV (2005) Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry 44, 67766787.
  • 158
    Kuczius T, Buschmann A, Zhang W, Karch H, Becker K, Peters G & Groschup MH (2004) Cellular prion protein acquires resistance to proteolytic degradation following copper ion binding. Biol Chem 385, 739747.
  • 159
    Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I, Perugini M, White AR, Cherny RA, Masters CL et al. (2001) Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106–126. Biochemistry 40, 80738084.
  • 160
    Fukuuchi T, Doh-ura K, Yoshihara S & Ohta S (2006) Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug. Bioorg Med Chem Lett 16 59825987.
  • 161
    Orem NR, Geoghegan JC, Deleault NR, Kascsak R & Supattapone S (2006) Copper (II) ions potently inhibit purified PrPres amplification. J Neurochem 96, 14091415.
  • 162
    Hijazi N, Shaked Y, Rosenmann H, Ben-Hur T & Gabizon R (2003) Copper binding to PrPC may inhibit prion disease propagation. Brain Res 993, 192200.
  • 163
    Haigh CL, Edwards K & Brown DR (2005) Copper binding is the governing determinant of prion protein turnover. Mol Cell Neurosci 30, 186196.
  • 164
    Percival SS (1998) Copper and immunity. Am J Clin Nutr 67, 1064S1068S.